ACE (angiotensin converting enzyme) inhibitory peptide derived from soybean protein isolate

By fermenting soy protein isolate by Lactobacillus Swiss, Asp-Phe-Leu (DFL) peptide with high ACE inhibitory activity was screened, which solved the problem of adverse reactions to existing hypertensive drugs and provided a safer and more efficient ACE inhibitor. for hypertension treatment and functional food.

CN119060122APending Publication Date: 2024-12-03CHONGQING UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410924083.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-02
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

Although existing hypertensive drugs can control blood pressure by inhibiting ACE activity, they often cause serious adverse reactions, such as headaches, allergic reactions and renal failure, and research on the development of bioactive peptides has not fully utilized the potential of soy protein isolate.

Method used

Soy protein isolate fermented by Lactobacillus Swiss, and separated and purified by 3kDa ultrafiltration centrifuge tube. The polypeptide liquid with molecular weight <3kDa was identified by liquid chromatography and mass spectrometry. The amino acid sequence Asp-Phe-Leu with ACE inhibitory activity was screened out ( DFL) as ACE inhibitor peptide.

Benefits of technology

The prepared ACE inhibitory peptide DFL has a higher ACE inhibitory activity (IC50 is 0.67 mg/mL), which can be used for hypertension treatment or as a functional food additive, providing safer and more efficient drug or food choices.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119060122A_ABST
    Figure CN119060122A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of bioactive peptides. The invention discloses an ACE (Angiotensin Converting Enzyme) inhibitory peptide derived from soybean protein isolate. The amino acid sequence of the ACE inhibitory peptide is Asp-Phe-Leu (DFL). In-vitro experiments show that the polypeptide has good ACE inhibitory activity, and IC50 is 0.67 mg / mL. The ACE inhibitory peptide provided by the invention has the characteristics of simple structure, strong activity and the like, is easy to produce, and can be tried to be used for developing drugs or functional foods with antihypertensive characteristics.
Need to check novelty before this filing date? Find Prior Art

Description

Technical field:

[0001] The invention relates to the technical field of bioactive peptides, and in particular to an ACE inhibitory peptide derived from soybean protein isolate. Background technology:

[0002] Hypertension is a common global chronic disease with an increasing incidence, which poses a serious threat to human health. At present, conventional hypertension treatment mainly relies on drug therapy, such as calcium channel blockers, β-receptor blockers, angiotensin converting enzyme (ACE) inhibitors, etc. Among them, widely used antihypertensive drugs mainly target ACE, a key target. Drugs inhibit the activity of ACE by binding to it, thereby reducing the production of angiotensin II, thereby achieving the effect of vasodilation and lowering blood pressure. Although these drugs have achieved certain results in controlling blood pressure, frequent intake of these drugs can cause serious adverse reactions, such as headaches, allergic reactions, and renal failure. In recent years, bioactive peptides have attracted much attention. They have the advantages of wide sources, easy access, and low toxicity. In particular, their multiple biological activities make them promising candidates for the treatment of various diseases.

[0003] As a high-quality protein that is easily available, soybean protein products are often used to make nutritional health products and are very popular, with broad market prospects. For example, infant formula milk uses a large amount of fully hydrolyzed soybean decomposed amino acids. Soy protein isolate is rich in hydrophobic amino acids such as L, F, V, I, and A, and is a potential raw material for the preparation of ACE inhibitory peptides. Research and development in the production of ACE inhibitory peptides by fermentation of soy protein isolate can effectively utilize soy protein isolate, increase the added value of soybeans, and realize the comprehensive utilization of resources. Therefore, fermenting soy protein isolate to produce ACE inhibitory peptides is of great significance for the development of safer and more efficient drugs or functional foods. Summary of the invention:

[0004] The invention provides an ACE inhibitory peptide derived from soybean protein isolate.

[0005] To achieve the above objectives, the following technical solutions are adopted:

[0006] The present invention provides an ACE inhibitory peptide, wherein the amino acid sequence of the ACE inhibitory peptide is Asp-Phe-Leu (DFL).

[0007] Furthermore, the ACE inhibitory peptide is derived from natural extraction of soy protein isolate or artificial amino acid synthesis.

[0008] The present invention provides a method for preparing the ACE inhibitory peptide, comprising the following steps:

[0009] Lactobacillus helveticus was used to ferment soybean protein isolate, and the fermentation conditions were fermentation temperature of 37.28°C, fermentation time of 48.9h, and inoculation amount of 6.2%. After fermentation, a 3kDa ultrafiltration centrifuge tube was used for separation and purification. The polypeptide liquid with a molecular weight of less than 3kDa was collected and vacuum freeze-dried and stored at -20°C for use. The amino acid sequence of the lyophilized powder with a molecular weight of less than 3kDa was identified by liquid chromatography-mass spectrometry (LC-MS / MS) to obtain the amino acid sequence DFL of the ACE inhibitory peptide.

[0010] The advantages of the present invention are:

[0011] The present invention ferments soybean protein isolate with Lactobacillus helveticus, purifies the fermentation broth, selects the best active component, i.e., the component with molecular weight less than 3 kDa, for amino acid sequence identification, and screens out a new amino acid sequence with ACE inhibitory activity; the ACE inhibitory peptide DFL prepared by the present invention has strong ACE inhibitory activity, and its IC 50 The activity of ACE inhibitory peptide is 0.67 mg / mL, which is higher than that of most existing ACE inhibitory peptides. The ACE inhibitory peptide can be used to prepare hypertension treatment / prevention drugs, or as a functional food additive for long-term health care of hypertension patients. Description of the drawings:

[0012] Figure 1 is the mass spectrum of ACE inhibitory peptide DFL;

[0013] Figure 2 To determine the activity of the ACE inhibitory peptide DFL. Specific implementation method:

[0014] This embodiment is implemented on the premise of the technical solution of the present invention, and provides detailed implementation methods and processes, but the protection scope of the present invention is not limited to the following implementation examples.

[0015] Example 1

[0016] The present embodiment provides an ACE inhibitory peptide derived from soybean protein isolate, whose amino acid sequence is DFL, which is obtained by extraction from soybean protein isolate, and the specific extraction process is as follows:

[0017] Lactobacillus helveticus was used to ferment soybean protein isolate, and the fermentation conditions were fermentation temperature of 37.28°C, fermentation time of 48.9h, and inoculation amount of 6.2%. After fermentation, 3kDa ultrafiltration centrifuge tube was used for separation and purification. The polypeptide liquid with molecular weight <3kDa was collected, vacuum freeze-dried, and stored at -20°C for future use.

[0018] The amino acid sequence of the lyophilized powder with a molecular weight of less than 3 kDa was identified by liquid chromatography-mass spectrometry (LC-MS / MS) to obtain the amino acid sequence DFL of the ACE inhibitory peptide, such as Figure 1 .

[0019] Example 2

[0020] The invention adopts a solid phase synthesis method to synthesize soybean protein isolate ACE inhibitory peptide DFL.

[0021] Example 3

[0022] The ACE inhibitory activity of DFL was determined by high performance liquid chromatography. The specific operation steps are as follows: First, 10 μL of substrate (HHL, 5 mM) was mixed with 100 μL of sample or sodium borate buffer (pH = 8.3, 0.1 M boric acid, 0.3 M sodium chloride), incubated at 37 ° C for 5 min, and 20 μL of ACE solution (0.1 U / L) was added to start the reaction. Then, after reacting at 37 ° C for 30 min, 90 μL of HCl (1 M) was added to terminate the reaction, and the peak area at 228 nm was determined by high performance liquid chromatography. The sample, substrate HHL, and ACE solution were all prepared with sodium borate buffer. The peak area of ​​the mixture was measured at 228 nm using an HPLC system (LC-20A, Shimadzu co., Japan) and an InertSustain AQ-C18 column (4.6 × 150 mm, 5 μm). The HPLC analysis conditions were set as follows: mobile phase A (0.05% TFA in ultrapure water) and mobile phase B (ACN) in a volume ratio of 25:75, isocratic elution at a flow rate of 1 mL / min for 10 min, column temperature of 30°C, and injection volume of 10 μL.

[0023] The ACE inhibition rate (%) was calculated according to the following formula:

[0024]

[0025] Among them, A blank and A sample Represent the peak areas of the blank (sodium borate buffer) and the HA chromatographic peak in the sample, respectively.

[0026] IC 50 It refers to the concentration of the corresponding peptide sample when ACE reaches 50% inhibition effect, calculated according to the regression curve of the component.

[0027] from Figure 2 It can be concluded that the ACE inhibitory activity IC of DFL 50 It was 0.67 mg / mL, indicating that the peptide had high ACE inhibitory activity.

[0028] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principles of the present invention should be included in the protection scope of the present invention.

Claims

1. An ACE inhibitory peptide derived from soy protein isolate, characterized in that: The amino acid sequence of the ACE inhibitory peptide is Asp-Phe-Leu.

2. A soybean protein isolate ACE inhibitory peptide according to claim 1, characterized in that: The ACE inhibitory peptide is derived from natural extraction or artificial synthesis of soy protein isolate.

3. A method for preparing a soybean protein isolate ACE inhibitory peptide as claimed in claim 1, characterized in that: Separation and purification from soybean protein isolate fermentation broth, the specific steps include the following: (1) Lactobacillus helveticus was used to ferment soybean protein isolate, and the fermentation conditions were as follows: fermentation temperature 37.28°C, fermentation time 48.9h, and inoculation amount 6.2%. After fermentation, a 3kDa ultrafiltration centrifuge tube was used for separation and purification. The polypeptide liquid with a molecular weight of less than 3kDa was collected and freeze-dried in vacuum, and stored at -20°C for later use; (2) The amino acid sequence of the lyophilized powder with a molecular weight of less than 3 kDa was identified by liquid chromatography-mass spectrometry (LC-MS / MS) to obtain the amino acid sequence of the ACE inhibitory peptide.

4. Use of the soybean protein isolate ACE inhibitory peptide as claimed in claim 1 in ACE inhibitory drugs and auxiliary blood pressure lowering health foods.